We are excited to announce that o2h discovery was the Finalist in the prestigious ‘Best Performing R&D Service Provider of the Year’ at ON Awards 2024 organised by One Nucleus, a not-for-profit Life Sciences & Healthcare organisation. The ‘Best Performing R&D Service Provider of the Year‘ category acknowledges organisations that have demonstrated remarkable achievements in the field of drug discovery services. This recognition highlights our dedication to providing outstanding drug discovery research services that drive innovation and progress within the biotech industry. o2h dis ..read more

The conference served as a platform for stimulating discussions, idea exchange, and networking opportunities to facilitate collaborative innovation. Ahmedabad: o2h Group, based out of Ahmedabad, India and Cambridge, UK, a leading investor in emerging life science and tech companies, hosted the 6th o2h Collaborative Innovation Conference in Ahmedabad, bringing together participants from diverse sectors. The conference served as a platform for stimulating discussions, idea exchange, and networking opportunities aimed at facilitating collaborative innovation. The conference witnessed engaging se ..read more

Biotech businesses benefit society by addressing unmet scientific and medical needs. However, there remains untapped potential for accelerating the market adoption of their breakthrough solutions. In the dynamic world of biotechnology, startups emerge as the pioneers of innovation, pushing the boundaries of scientific discovery. These prospective ventures bring new perspectives, game-changing novel drug/therapeutic concepts, and the development of novel chemical entities (NCEs) to the table. However, the path from concept to success is frequently loaded with difficulties for the small molecul ..read more

Over the last two decades, Surface Plasmon Resonance (SPR) has evolved into a crucial label-free detection approach, revolutionising biomolecular interaction studies in clinical settings. This technology enables high-sensitivity real-time measurement of interactions without the use of labels. Label-free detection eliminates the requirement for specialised tags or dyes, allowing for more sensitive measurement of target analytes and the use of native biomolecules appropriate for biologically relevant methods. Since its introduction in the early 1990s, SPR has proven to be one of the m ..read more

Can you imagine a world in which we could selectively erase disease-causing proteins from our bodies, leaving healthy cells unaffected? This revolutionary concept is not science fiction; it’s the promise of targeted protein degradation (Protac Services), a cutting-edge approach that holds the potential to transform medicine as we know it. Targeted Protein Degradation (TPD) with it’s PROTAC Services, promisingly offers a novel way to eliminate toxic or disease-associated targets from cells. New medicines are being developed that leverage the cell’s intrinsic destruction machinery (ubiquitin-pr ..read more

Some of the challenges faced by biotech startups: Early-stage biotech startups often face a range of challenges, from limited funding and complex regulatory and inventory requirements to scientific hurdles, intense competition, time and resource management. The complexities of drug development and the highly competitive nature of the biotech industry make it challenging for startups to navigate these hurdles successfully, leading to possible setbacks and delays in reaching their milestones. All these biotech startup challenges can possibly affect their progress to the next milestone in their ..read more

CITC (Chemistry in the Cloud)TM has won the “Best Use of Technology Award” o2h discovery is absolutely thrilled to announce that our in-house built proprietary app CITC (Chemistry in the Cloud)TM has won the category “Best Use of Technology Award” in the Pharma Industry Awards UK 2023.                                 CITC won the Best Use of Technology Award The Pharma Industry Awards UK 2023 is dedicated to identifying and celebrating the most original and innovative individuals and companies that demonst ..read more

We have recently announced the launch of the 5th edition of o2h kickstarter, exclusively to support USA-based early-stage biotech companies to boost their drug discovery program. The  competition is Live now and the last date to apply is October 10th… The aim of the o2h kickstarter 5.0 is to support the next wave of USA based biotechnology companies that have secured initial funding, have exciting drug targets, and have the ability to scale, but need expert services to supercharge their chemistry efforts to meet the next scientific and funding milestones.  Meet the o2h kickstarter ..read more

Building on the success of our earlier kickstarter competition in the UK, Australia, Israel, and Italy, we are excited to announce the launch of the 5th edition of o2h kickstarter, exclusively tailored for early-stage biotech companies based in the USA. o2h discovery has now supported many companies through launching its Discovery kickstarter competition in several of the world’s most exciting biotech clusters, and now we aim to bring our biotech start-up machinery to the largest and most successful biotech ecosystems in the world, the USA. o2h discovery has been working with Venture Capital ..read more

o2h discovery, a preclinical Contract Research Organization which has integrated drug discovery capabilities operating from its state-of-the-art research facilities in Ahmedabad, India and Cambridge, UK, is pleased to announce the fifth edition of the o2h kickstarter competition exclusively aimed towards supporting early-stage biotech companies based in the United states. US Biotech startups have always stayed at the forefront of innovation, revolutionising healthcare. Their journey involves cutting-edge research, leveraging AI and precision medicine, to develop transformative drugs. Their fo ..read more